EPO

EPO (Erythropoietin)

EPO (Erythropoietin) is a research-grade recombinant glycoprotein hormone developed for preclinical investigation of erythropoiesis, hypoxia signalling, and haematopoietic regulation. Endogenously produced primarily by the kidneys in response to hypoxia, erythropoietin is the principal regulator of red blood cell production, acting on erythroid progenitor cells in the bone marrow. Recombinant EPO is a well-characterised tool compound used extensively in haematology, nephrology, and oxygen transport research.

Mechanism of Action

EPO binds to the erythropoietin receptor (EPOR) on erythroid progenitor cells in the bone marrow, activating the JAK2/STAT5 signalling pathway. This promotes the proliferation, differentiation, and survival of erythroid progenitors, ultimately increasing circulating red blood cell mass and haemoglobin concentration. Beyond erythropoiesis, EPO receptors have been identified in neural, cardiac, and endothelial tissues, and preclinical research has explored its cytoprotective and anti-apoptotic roles in non-haematopoietic contexts including neuroprotection and cardiac ischaemia models.

Research Applications

• Erythropoiesis and red blood cell production studies
• JAK2/STAT5 signalling pathway research
• Hypoxia response and HIF pathway investigation
• Neuroprotection and cytoprotection modelling
• Anaemia and haematopoietic disorder research models

Specifications

• Molecular Formula: Recombinant glycoprotein
• CAS Number: 113427-24-0
• Purity: ≥98%
• Molecular Weight: ~30,400 Da (glycosylated)
• Form: Lyophilised powder
• Storage: -20°C
• Shelf Life: 24 months

This product is intended for legitimate laboratory and analytical research use only. Not for diagnostic, therapeutic, or consumer use.